Chimeric Therapeutics Investor Relations Material

Chimeric Therapeutics Ltd is a biotechnology company focused on developing cell therapy treatments for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, aiming to harness the immune system to target solid tumors and hematologic malignancies. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.